Fibroblast growth factor 9 upregulates heme oxygenase-1 and γ-glutamylcysteine synthetase expression to protect neurons from 1-methyl-4-phenylpyridinium toxicity

Free Radical Biology and Medicine

Volumn 49, Issue 6, 2010, Pages 1099-1108

  Huang, Jui Yen ^a   Chuang, Jih Ing ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Fibroblast growth factor; Free radicals; Glutathione; Heme oxygenase 1; Hydrogen peroxide; Parkinson disease; Glutamylcysteine synthetase

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; FIBROBLAST GROWTH FACTOR 9; GLUTAMATE CYSTEINE LIGASE; GLUTAMATE CYSTEINE LIGASE INHIBITOR; GLUTATHIONE; HEME OXYGENASE 1; HEME OXYGENASE INHIBITOR; HYDROGEN PEROXIDE; LIGASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; BRAIN CORTEX; CELL DEATH; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; EMBRYO; INTOXICATION; MESENCEPHALON; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

EID: 77955516215     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.06.026     Document Type: Article

References (50)

1. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
2. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci. Lett. 1982, 33:305-310.
3. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., Raisman-Vozari R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. NeuroReport 1999, 10:557-561.
4. Chauhan N.B., Siegel G.J., Lee J.M. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J. Chem. Neuroanat. 2001, 21:277-288.
5. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 1999, 270:45-48.
6. Drechsel D.A., Liang L.P., Patel M. 1-Methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons. Toxicol. Appl. Pharmacol. 2007, 220:341-348.
7. Aoyama K., Matsumura N., Watabe M., Nakaki T. Oxidative stress on EAAC1 is involved in MPTP-induced glutathione depletion and motor dysfunction. Eur. J. Neurosci. 2008, 27:20-30.
8. +-induced death of dopaminergic neurons and is involved in melatonin neuroprotection in vivo and in vitro. J. Neurochem. 2009, 109:1400-1412.
9. Chinta S.J., Andersen J.K. Redox imbalance in Parkinson's disease. Biochim. Biophys. Acta 2008, 1780:1362-1367.
10. Smith M.P., Cass W.A. GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease. Neurosci. Lett. 2007, 412:259-263.
11. Georgievska B., Kirik D., Rosenblad C., Lundberg C., Bjorklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. NeuroReport 2002, 13:75-82.
12. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 1992, 59:99-106.
13. +-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J. Pineal Res. 2002, 32:262-269.
14. Chuang J.I., Chen T.H. Effect of melatonin on temporal changes of reactive oxygen species and glutathione after MPP(+) treatment in human astrocytoma U373MG cells. J. Pineal Res. 2004, 36:117-125.
15. Mason I. Initiation to end point: the multiple roles of fibroblast growth factors in neural development. Nat. Rev. Neurosci. 2007, 8:583-596.
16. Hsuan S.L., Klintworth H.M., Xia Z. Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways. J. Neurosci. 2006, 26:4481-4491.
17. Ohmachi S., Mikami T., Konishi M., Miyake A., Itoh N. Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c. J. Neurosci. Res. 2003, 72:436-443.
18. Hou J.G., Cohen G., Mytilineou C. Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: involvement of the glutathione system. J. Neurochem. 1997, 69:76-83.
19. Timmer M., Cesnulevicius K., Winkler C., Kolb J., Lipokatic-Takacs E., Jungnickel J., Grothe C. Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion. J. Neurosci. 2007, 27:459-471.
20. Corso T.D., Torres G., Goulah C., Roy I., Gambino A.S., Nayda J., Buckley T., Stachowiak E.K., Bergey E.J., Pudavar H., Dutta P., Bloom D.C., Bowers W.J., Stachowiak M.K. Transfection of tyrosine kinase deleted FGF receptor-1 into rat brain substantia nigra reduces the number of tyrosine hydroxylase expressing neurons and decreases concentration levels of striatal dopamine. Brain Res. Mol. Brain Res. 2005, 139:361-366.
21. Vargas M.R., Pehar M., Cassina P., Martinez-Palma L., Thompson J.A., Beckman J.S., Barbeito L. Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. J. Biol. Chem. 2005, 280:25571-25579.
22. 2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J. Neurochem. 1995, 65:1740-1751.
23. +-ATPase activity in hippocampal neurons. Brain Res. 1997, 756:205-214.
24. Cathcart R., Schwiers E., Ames B.N. Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. Anal. Biochem. 1983, 134:111-116.
25. Anderson M.E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 1985, 113:548-555.
26. Kamencic H., Lyon A., Paterson P.G., Juurlink B.H. Monochlorobimane fluorometric method to measure tissue glutathione. Anal. Biochem. 2000, 286:35-37.
27. White C.C., Viernes H., Krejsa C.M., Botta D., Kavanagh T.J. Fluorescence-based microtiter plate assay for glutamate-cysteine ligase activity. Anal. Biochem. 2003, 318:175-180.
28. Wu H., White C.C., Isanhart J.P., McBride T.J., Kavanagh T.J., Hooper M.J. Optimization and application of glutamate cysteine ligase measurement in wildlife species. Ecotoxicol. Environ. Saf. 2009, 72:572-578.
29. Dringen R. Metabolism and functions of glutathione in brain. Prog. Neurobiol. 2000, 62:649-671.
30. Naruo K., Seko C., Kuroshima K., Matsutani E., Sasada R., Kondo T., Kurokawa T. Novel secretory heparin-binding factors from human glioma cells (glia-activating factors) involved in glial cell growth: purification and biological properties. J. Biol. Chem. 1993, 268:2857-2864.
31. Schipper H.M., Song W., Zukor H., Hascalovici J.R., Zeligman D. Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J. Neurochem. 2009, 110:469-485.
32. Schipper H.M., Liberman A., Stopa E.G. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp. Neurol. 1998, 150:60-68.
33. Fernandez-Gonzalez A., Perez-Otano I., Morgan J.I. MPTP selectively induces haem oxygenase-1 expression in striatal astrocytes. Eur. J. Neurosci. 2000, 12:1573-1583.
34. +. NeuroReport 2004, 15:1039-1044.
35. Diaz-Hernandez J.I., Almeida A., Delgado-Esteban M., Fernandez E., Bolanos J.P. Knockdown of glutamate-cysteine ligase by small hairpin RNA reveals that both catalytic and modulatory subunits are essential for the survival of primary neurons. J. Biol. Chem. 2005, 280:38992-39001.
36. Chinta S.J., Kumar J.M., Zhang H., Forman H.J., Andersen J.K. Up-regulation of γ-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson's disease. Free Radic. Biol. Med. 2006, 40:1557-1563.
37. Hung S.Y., Liou H.C., Kang K.H., Wu R.M., Wen C.C., Fu W.M. Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridinium-induced neurotoxicity. Mol. Pharmacol. 2008, 74:1564-1575.
38. Salinas M., Diaz R., Abraham N.G. Ruiz de Galarreta, C. M.; Cuadrado, A. Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. J. Biol. Chem. 2003, 278:13898-13904.
39. Saavedra A., Baltazar G., Carvalho C.M., Duarte E.P. GDNF modulates HO-1 expression in substantia nigra postnatal cell cultures. Free Radic. Biol. Med. 2005, 39:1611-1619.
40. Lee D.W., Gelein R.M., Opanashuk L.A. Heme-oxygenase-1 promotes polychlorinated biphenyl mixture Aroclor 1254-induced oxidative stress and dopaminergic cell injury. Toxicol. Sci. 2006, 90:159-167.
41. Benvenisti-Zarom L., Regan R.F. Astrocyte-specific heme oxygenase-1 hyperexpression attenuates heme-mediated oxidative injury. Neurobiol. Dis. 2007, 26:688-695.
42. de Vries H.E., Witte M., Hondius D., Rozemuller A.J., Drukarch B., Hoozemans J., van Horssen J. Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?. Free Radic. Biol. Med. 2008, 45:1375-1383.
43. Weng Z., Signore A.P., Gao Y., Wang S., Zhang F., Hastings T., Yin X.M., Chen J. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. J. Biol. Chem. 2007, 282:34479-34491.
44. Chalovich E.M., Zhu J.H., Caltagarone J., Bowser R., Chu C.T. Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J. Biol. Chem. 2006, 281:17870-17881.
45. Chen P.C., Vargas M.R., Pani A.K., Smeyne R.J., Johnson D.A., Kan Y.W., Johnson J.A. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc. Natl Acad. Sci. USA 2009, 106:2933-2938.
46. Ramsey C.P., Glass C.A., Montgomery M.B., Lindl K.A., Ritson G.P., Chia L.A., Hamilton R.L., Chu C.T., Jordan-Sciutto K.L. Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 2007, 66:75-85.
47. Wright M.M., Kim J., Hock T.D., Leitinger N., Freeman B.A., Agarwal A. Human haem oxygenase-1 induction by nitro-linoleic acid is mediated by cAMP, AP-1 and E-box response element interactions. Biochem. J. 2009, 422:353-361.
48. Kronke G., Bochkov V.N., Huber J., Gruber F., Bluml S., Furnkranz A., Kadl A., Binder B.R., Leitinger N. Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein. J. Biol. Chem. 2003, 278:51006-51014.
49. Wing L.Y., Chen H.M., Chuang P.C., Wu M.H., Tsai S.J. The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation. J. Biol. Chem. 2005, 280:19937-19947.
50. Antoine M., Wirz W., Tag C.G., Gressner A.M., Marvituna M., Wycislo M., Hellerbrand C., Kiefer P. Expression and function of fibroblast growth factor (FGF) 9 in hepatic stellate cells and its role in toxic liver injury. Biochem. Biophys. Res. Commun. 2007, 361:335-341.